Richard Mark Kirkner SAN FRANCISCO ― A large observational registry study of almost 100,000 eyes has found that the diabetes drug semaglutide, a GLP-1 agonist recently approved for weight loss, does not worsen the progression of potentially vision-threatening diabetic retinopathy in the long term in patients taking the drug. However, the researchers said, the findings...
Tag: <span>diabetic retinopathy</span>
Post
AAO: Diabetic retinopathy usually no worse with semaglutide in T2D
by Elana Gotkine For patients with type 2 diabetes mellitus, most eyes have no worsening of diabetic retinopathy (DR) after initiation of semaglutide, according to a study presented at the annual meeting of the American Academy of Ophthalmology, held from Nov. 3 to 6 in San Francisco. Zeeshan Haq, M.D., from Retina Consultants of Minnesota...
Post
Studies Implicate GLP-1 Agonists in Progression of Diabetic Retinopathy
Ellen Kurek August 03, 2023 SEATTLE — A family of blockbuster drugs for managing blood glucose — and now for promoting weight loss — has been linked to exacerbation of macular disease that frequently accompanies diabetes, new data show. Two studies presented at the 2023 annual meeting of the American Society of Retina Specialists have found that...
Post
Studies Implicate GLP-1 Agonists in Progression of Diabetic Retinopathy
Ellen Kurek August 03, 2023 SEATTLE — A family of blockbuster drugs for managing blood glucose — and now for promoting weight loss — has been linked to exacerbation of macular disease that frequently accompanies diabetes, new data show. Two studies presented at the 2023 annual meeting of the American Society of Retina Specialists have found that...
Post
The role of caffeine in preventing diabetic retinopathy
By Suchandrima Bhowmik Mar 5 2023 Reviewed by Benedette Cuffari, M.Sc. Diabetic retinopathy (DR) is an ophthalmological complication of diabetes that is the primary cause of vision loss and blindness in this patient population. DR is a frequent microangiopathic complication in Catalonia, Spain, with its incidence expected to increase due to the rise in diabetes,...
Post
Family Doctors May Be Effective at Detecting Diabetic Retinopathy
BY QUINN PHILLIPS | NOVEMBER 10, 2022 Family doctors may be effective at identifying diabetic retinopathy despite not being eye specialists, according to the results of a new study designed to test their ability to do so. The study was presented at 2022 meeting of the American Academy of Ophthalmology, and described in an article at Healio. Diabetic...
Post
Multicenter cohort study shows reduced risk of vision-threatening diabetic retinopathy from fenofibrate
by Bob Yirka, Medical Xpress Credit: Jenriquecf/Wikimedia Commons, CC BY-SA 4.0 A team of researchers at the University of Pennsylvania has found that administration of a drug currently used to reduce cholesterol levels in the bloodstream can reduce the risk of developing proliferative diabetic retinopathy (PDR) from non-proliferative diabetic retinopathy (NPDR). In their paper published in JAMA Ophthalmology, the...
Post
Study: Youths who use insulin pumps less at risk for diabetic retinopathy
by Johns Hopkins University School of Medicine Credit: Pixabay In one of the largest and most racially diverse studies to date of American children and adolescents with type 1 and type 2 diabetes, researchers at Johns Hopkins Medicine, Baylor College of Medicine and the University of Wisconsin have identified the clinical and demographic factors associated with pediatric diabetic...
Post
AI SPOTS EARLY EYE CHANGES THAT SIGNAL DIABETIC RETINOPATHY
During its early stages, diabetes can affect the eyes before the changes are detectable with a regular clinical examination. New research shows these changes can be measured earlier than previously thought with specialized optical techniques and computer analysis. The ability to detect biomarkers for this sight-threatening condition may lead to the early identification of people at risk...
Post
New antibody therapy may reverse diabetic retinopathy and other eye conditions
by Eileen Hoftyzer, University of Toronto Professors Stéphane Angers and Sachdev Sidhu pictured in the Donnelly Centre before the COVID-19 pandemic. Credit: University of Toronto The life-saving diabetic medication insulin, developed at the University of Toronto 100 years ago, was the first biologic therapy—a protein to treat disease. A century later, a new biologic therapy also...
- 1
- 2